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ABSTRACT 
Spinal cord stimulation (SCS) is an interventional on-pharmacologic treatment used for chronic 
pain and other indications. Methods for evaluating he safety and efficacy of SCS have evolved 
from uncontrolled and retrospective studies to prosective randomized controlled trials (RCTs). 
While randomization overcomes certain types of bias, additional challenges to the validity of 
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variables (e.g., paresthesia, device programming and recharging, psychological support, and 
rehabilitative techniques), and safety considerations. In order to address these challenges, three 
professional societies (IMMPACT, ION, INS) convened a meeting to develop consensus 
recommendations on the design, conduct, analysis, and interpretation of RCTs of SCS for 
chronic pain. This paper summarizes the results of his meeting. Highlights of our 
recommendations include disclosing all funding source and potential conflicts; incorporating 
mechanistic objectives when possible; avoiding non-inferiority designs without internal 
demonstration of assay sensitivity; achieving and documenting double-blinding whenever 
possible; documenting investigator and site experience; keeping all information provided to 
patients balanced with respect to expectation of benefit; disclosing all information provided to 
patients, including verbal scripts; using placebo/sham controls when possible; capturing a 
complete set of outcome assessments; accounting for ancillary pharmacologic and non-
pharmacologic treatments in a clear manner; providing a complete description of intended and 
actual programming interactions; making a prospectiv  ascertainment of SCS-specific safety 
outcomes; training patients and researchers on appropriate expectations, outcome assessments, 
and other key aspects of study performance; and providing transparent and complete reporting of 
results according to applicable reporting guidelines. 
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1.  Introduction 
Chronic pain that is refractory to conventional medical management is common and is associated 
with high costs and significant consequences to individuals and society [72]. Spinal cord 
stimulation (SCS) has been used since the 1960s to treat refractory chronic pain and other 
conditions, including intractable angina and limb ischemia [127]. SCS is a type of 
“neuromodulation,” which encompasses methods to stimulate the nervous system as well as 
intrathecal drug delivery. Other neuromodulation techniques include peripheral nerve stimulation 
for pain and deep brain stimulation for Parkinson’s disease and other indications [17,67]. The 
key goal of neuromodulation is relief of an otherwise refractory condition without pharmacologic 
side effects. SCS requires invasive procedures, including the implantation of devices, and 
therefore engenders risks, some of which might leadto reoperation, including infection, 
mechanical failure, and neurologic injury. 
As with any treatment, a thorough benefit-risk asses ment is required for SCS to allow patients, 
clinicians, researchers, regulatory authorities, and reimbursement agencies to determine its place 
in therapy. Methods for designing and conducting clinical trials to generate such evidence have 
evolved over the past half century; it is widely accepted that various levels of evidence are 
generated using      various trial methods that provide different levels of confidence in the study 
results. While real-world evidence generated from registries and case series can provide valuable 
insights, international consensus has accepted the randomized, controlled trial (RCT) (or meta-
analyses of such trials) as the highest level of evidence of the efficacy of a treatment [12]. The 
quality of evidence provided by RCTs, however, can v ry widely depending on the quality of 
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determining the factors that generate credible clinical trial results must go beyond simply 
advocating for an RCT. 
As with other invasive procedures, clinical trials of SCS are associated with special challenges 
compared with studies of pharmaceuticals.  Examples include difficulties with blinding, choice 
of control groups, the fact that permanent implants may occur only in patients who have had 
successful trial periods, non-specific accompaniments to treatment (such as paresthesia or lack 
thereof, device programming and recharging, psychological support, and rehabilitative 
techniques), and special safety considerations. Simply randomizing study subjects to an active or 
control condition does not fully address these issue . 
Authorities of various types have various roles with regard to market access and reimbursement.  
Standards for medical device studies of these organizations differ among jurisdictions and do not 
mandate RCT evidence; however, expectations about the design and conduct of trials to ensure 
the safety and effectiveness of devices have been increasing.  Payers expect robust trial data to 
inform reimbursement decisions, which may include health-related quality of life, return to work 
and work productivity, long-term safety, and the total cost of care, in addition to fundamental 
design principles. Several important research questions, such as long-term safety, healthcare use, 
and costs, are generally not answered by RCTs; consequently, consideration of real-world data 
(RWD) or real-world evidence (RWE) is required to fill these gaps [135]. 
Based on the issues outlined above, achieving consensu  on standards for the design, conduct, 
analysis, and reporting of RCTs of SCS for pain is an urgent priority. Such standards can drive 
the generation of high-quality information that will inform stakeholders in their efforts to 
improve the treatment of chronic pain with SCS and related techniques.  After extensive 
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this report, since they do not strictly speaking involve stimulation of the spinal cord; however, 
we invite readers interested in the design of those studies to consider our recommendations, since 
similar principles apply. 
 
2.  Methods 
In November 2018, the Initiative on Methods, Measurement, and Pain Assessment in Clinical 
Trials (IMMPACT), the Institute of Neuromodulation (ION), and the International 
Neuromodulation Society (INS) convened a meeting with the aim of developing 
recommendations regarding the design and conduct of clinical trials of SCS for the treatment of 
pain.1 While the focus of the meeting was SCS for pain, many considerations apply to other 
medical devices for the treatment for pain and other conditions, particularly where subjective 
endpoints are evaluated. Meeting participants were s l cted for their expertise in preclinical and 
clinical research, administration, policy, and clini al care related to SCS or in conducting and 
interpreting clinical trials. The meeting was intend d to generate general recommendations that 
would address a broad set of issues related to SCS clinical trials; thus, the composition of the 
meeting reflected a broad representation of relevant disciplines and perspectives (e.g., 
anesthesiologists, neurologists, psychologists, basic scientists, pain experts, clinical trialists, 
health economists, manufacturers) from a number of countries, while limiting the overall 
meeting size in order to promote fruitful and efficient discussion.  All companies identified as 
                                                          
1
 IMMPACT is a consortium of individuals from academia, government agencies (e.g. Food and Drug Administration 
[FDA], National Institutes of Health [NIH]), pharmaceutical and device companies, and patient advocacy and 
research organizations; ION is a consortium of multidisciplinary experts in the field of neuromodulation with an 
aim to promote research and innovation to advance the field of neuromodulation to improve health and quality of 
life for patients; and INS is a global professional membership society dedicated to be a forum and disseminator of 
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manufacturers of spinal cord stimulators were invited to participate in order to ensure that their 
insights and perspectives were represented.   The cont nt of this paper represents the consensus 
of all authors and no editorial control was vested in any specific authors or groups. 
A set of background articles was circulated prior to the meeting so that participants would be 
familiar with all relevant issues. In addition, background lectures presented by several of the 
authors of this article2 covered a broad range of relevant clinical research design issues.3 After 
the meeting, additional literature searches were conducted, reviewed, and incorporated into the 
summary of the discussions and recommendations. 
3.  The history of research on the mechanisms, efficacy, and safety of spinal cord 
stimulation 
Early work by Bishop and Landau had shown that when large diameter fibers in peripheral 
nerves were blocked, pain resulting from activation of smaller diameter fibers that mediated pain 
sensation was enhanced [5].  These observations gave rise to the Gate Control Theory of Pain, 
which posited that large diameter nerve fibers dampened the input from small diameter pain 
fibers at a “gate” in the dorsal horn of the spinal cord, thus increasing interest in methods to 
selectively stimulate large diameter nerve fibers to enhance this inhibitory effect [103]. The first 
attempt to accomplish this applied electrical stimulation to the infraorbital nerve [161]. 
Unfortunately, peripheral nerve stimulation of other mixed peripheral nerves is sometimes 
limited by the fact that thresholds for motor efferents are similar to those for large sensory 
afferents, producing uncomfortable motor effects. In the human dorsal columns, however, 
primary afferents are conveniently segregated from motor fibers. The first report of an 
                                                          
2
 S.E., J.G., S.H., B.K., N.K., E.M., J.M., R.N., C.P., A.R., R.S, R.T., S.T. 
3
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implantable SCS device was from Shealy in 1967 [137]. When physiologic studies suggested 
that SCS stimulates spinal cord structures beyond the dorsal column, terminology transitioned 
from “dorsal column stimulation” to “spinal cord stimulation.” Critics of the gate control theory 
[23,106] also suggested that the mechanism of action of SCS might be more complex than 
initially believed; thus, many studies have been coducted on the mechanism of pain relief 
produced by SCS [94,95]. 
Initial reports on SCS indicated that about 50% success rate in implanted patients [126]; later 
reports with longer follow-up and new assessors reporting success rates as low as 15% [39]. Trial 
stimulation was introduced in 1975 [38] as a method for assessing initial responsiveness before 
implantation, and independent third-party follow-up was introduced in 1977 to reduce observer 
bias [110]. Researchers also began to improve the comprehensiveness of outcome assessment 
and reporting. Clinical research progressed from mechanistic studies and uncontrolled clinical 
studies to controlled trials comparing devices and stimulation paradigms. Studies that focused on 
safety began documenting technical complications, including electrode migration and lead 
failures [110]. Safety has been given increased attention with the publication of studies on 
specific complications and of comprehensive reviews [19,34,62,91]. Studies designed to evaluate 
clinical outcomes as well as mechanisms of action, including recent studies of SCS-induced pain 
relief with fMRI, demonstrated the usefulness of combining these approaches 
[90,92,101,128,163]. To date, more than 2500 citations of studies of SCS that report primary 
data appear on The Neuromodulation Foundation’s searchable database (www.wikistim.org) 
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4.  Types of spinal cord stimulation 
SCS electrodes are implanted in the epidural space over the dorsal aspect of the spinal cord. 
Manipulation of stimulation parameters is thought to allow for preferential targeting of specific 
fibers or cells to produce different effects [11,95]. SCS is categorized based on stimulation 
attributes such as frequency, tonicity, induction of paresthesia, and use of feedback to adjust 
stimulation [11,123] (Table 1). The traditional form of SCS uses relatively low frequencies, 
generally induces paresthesia, and is commonly called “tonic”; however, because the term 
“tonic” strictly speaking applies to any waveform with a constant amplitude and evenly-spaced 
pulses, in this paper the term “low frequency” will be used. More recently introduced types of 
SCS use higher frequencies (e.g., 10kHz or “high density” stimulation) or deliver multiple pulses 
in quick succession in each stimulation phase (“burst stimulation”). These other SCS categories 
are programmed at amplitudes generally below the par sthesia threshold. All SCS therapies are 
challenged by the ever-changing distance between the electrode and the spinal cord with patient 
movement, the cardiorespiratory cycle, and coughing [68], which might contribute to variability 
in clinical outcomes [165]. For this reason, investigators developed “closed-loop,” which 
measures the evoked compound action potential (ECAP) from the spinal cord after each pulse 
and automatically adjusts the strength of the next pulse to maintain a specified ECAP size 
[101,128,129]. In principle, stimulation parameters also may be adjusted based on other inputs, 
such as accelerometers and time-of-day, and they may be interleaved, "shuffled," or otherwise 
varied in innumerable ways [89,112]. New approaches to SCS are under continual development, 
including efforts to preferentially stimulate the dorsal horn by delivering a broad field shape by 
using multiple independent contacts, and multiplexed stimulation with targets that include glial 
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are programmed to produce perceptible paresthesia and others are not, which creates challenges 
in blinding and measurement of paresthesia.  In addition to the multiple approaches outlined 
above, SCS advances have also resulted in improved typ s of SCS electrodes (Fig. 1A), pulse 
generators (Fig. 1B), and power sources. 
 
5.  Systematic review of methods in randomized controlled trials of spinal cord stimulation 
for pain 
A systematic review of research methods of SCS RCTs for pain was performed to inform the 
discussion of clinical trial standards; results of this review, to be published elsewhere, are 
summarized here, excluding studies on angina.  The dat s of study manuscripts ranged from 
1994-2018. Most of the 34 RCTs studying pain focused on back or leg pain, including failed 
back surgery syndrome (FBSS). The majority of studies (n=20) used a crossover design, 
although a substantial minority (n=14) used a parallel design. Most studies reported on subjects 
who received low-frequency SCS (n=22), with fewer studies covering high-frequency (n=8), 
burst (n=6), or other waveforms (n=1). The most common control group was low-frequency SCS 
(n=13), followed by placebo on/off (the device could be turned off) (n=10), usual care (n=8), 
physical therapy (n=2), and surgery (n=1). Trial stimulation was included in about half of the 
studies, and most studies (60%) allowed programming adjustments after randomization. Co-
administration of non-invasive pain treatments was specifically allowed in most studies (65%), 
unspecified in about one third, and prohibited in one.  Most studies did not specify among the 
eligibility criteria the willingness of patients todiscontinue or keep concomitant medications 
stable, failure of more conservative treatments, mini um pain intensity, or pain duration. The 
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0-208 weeks). The primary endpoint was specified in nearly all studies; pain intensity was the 
most frequent. About a third of studies had multiple rimary outcomes; few addressed 
adjustment for multiplicity. Reporting of primary and secondary endpoints was often unclear. 
Most studies did not specify how adverse events (AEs) were collected. AEs of special interest, 
which can significantly affect the outcome of SCS and re not normally subject to specific data 
collection and reporting in clinical trials (e.g., fractured electrodes, infection), were reported in a
minority of studies; among these, a clear method for pr spectively capturing them was seldom 
prespecified. The primary hypothesis was superiority in about half of the studies (n=18), with 
fewer studies designed as noninferiority (n=4) or equivalence studies (n=1), and the remainder 
not specifying (n=11). The primary analysis cohort was intention-to-treat (ITT) or modified ITT 
in about a third, with a few reporting both a per-protocol and an ITT analysis. Few studies 
reported a method for accounting for missing data; the most common method reported was last 
observation carried forward (LOCF). Sample size calcul tions were reported in about two-thirds. 
The median number of participants completing the prima y analysis was 33. The method of 
randomization was assessed as having a low risk of bias in most studies (e.g., computer 
generated randomization) but was not specified (higher risk of bias) in about a third. The 
majority was unblinded (68%). Half were single-center studies and half multi-center; only a 
minority noted registration. Most studies reported funding sources; of those, all were industry-
funded. 
In summary, many studies failed to adhere to basic elements of clinical research methodology 
[55,56,65,99], including clear eligibility criteria, clear process of randomization, blinding, 
standardized patient management, pre-specification of a alysis methods, comprehensive 
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study interventions, and transparency (registration of the study and disclosure of funding sources 
and conflicts). Thus, while these studies were all ostensibly RCTs, inadequacies in study design, 
analysis, conduct, and reporting undermine the credibility of the conclusions. 
 
6.  Objectives, comparators, and research designs 
A well-designed RCT begins with a study objective, or hypothesis, framed in terms of the 
comparison of a test treatment with one or more comparators. There are three basic approaches: 
(1) Superiority studies evaluate whether one treatment is better than another. (2) Non-inferiority 
studies evaluate whether the test treatment is no worse than the reference (by an acceptable 
amount, called the non-inferiority [NI] margin) (Fig. 2). The presumption is that the new 
treatment has some other advantage (e.g., in terms of availability, cost, invasiveness, safety, etc.). 
(3) Equivalence studies aim to show that a new treatment is neither better nor worse than a 
reference treatment by a specified difference; this approach is common in pharmacokinetic 
studies, and is infrequently performed in drug or device studies. 
The advantages of superiority designs are clarity of interpretation (although statistical superiority 
and clinical superiority must be considered separately) and smaller sample size requirements 
(compared with non-inferiority and equivalence design ).  In pharmaceutical studies, 
demonstration of superiority over placebo has been considered synonymous with efficacy, 
largely because randomization, double-blinding, and equal management of patients in both study 
arms mitigate biases that inflate the observed efficacy of the study treatment. The fundamental 
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a few RCTs [1,145]; however, because measures to control these biases generally have not been 
implemented, conclusions of superiority are difficult to substantiate. 
Non-inferiority is achieved when the lower limit ofthe 95% confidence interval around the 
observed effect of treatment excludes the NI margin; th s is interpreted to mean that the 
possibility of the true effect of the test treatment being worse than the reference treatment 
beyond the specified threshold has been excluded. Various approaches are available for selecting 
non-inferiority margins [36,122].  The rationale for non-inferiority designs must include 
evidence for the efficacy of the comparator treatment (e.g., a superiority study vs. placebo) 
[122]. Because of the high and variable placebo respon e rate in pain trials [37], demonstration 
of superiority of the comparator to placebo in a previous clinical trial does not guarantee that the 
comparator would have been superior to placebo in the current trial. Therefore, non-inferiority 
studies of treatments for pain are not scientifically valid in the absence of an internal 
demonstration of assay sensitivity (and consideration of biases, see below) [47]. Internal 
demonstration of assay sensitivity can be achieved by emonstration of superiority of any active 
treatment over sham treatment or by superiority of one treatment group over another.  Failing to 
implement measures to control sources of measurement error (e.g., accuracy of pain reporting, 
inter-site variability, concomitant pain treatments) increases the likelihood of a finding of non-
inferiority, since measurement error makes it virtually impossible to differentiate treatments that 
are in fact different – the only practical way to ensure that such sources of measurement error 
have been controlled is an internal demonstration of superiority of one group over another (assay 
sensitivity).  (A similar issue applies to a superiority study that fails to demonstrate a between-
group difference: it can be challenging to discern whether the lack of a difference was due to a 
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treatments.)  An additional disadvantage of non-infer ority designs is the requirement for a large 
sample size, potentially four times the size of a superiority study, depending upon the choice of 
non-inferiority margins and other assumptions. 
The choice of comparator in SCS studies is driven by the study objectives/hypotheses. Options 
include: (1) Comparison of a test stimulation paradigm with sham4 using the same device. For 
example, implanting a single type of device then enteri g patients into a crossover study 
comparing one stimulation paradigm with sham stimulation using that device [1,146]. (2) 
Comparison of a test stimulation paradigm to a comparator stimulation paradigm using the 
same device [109]. (3) Comparison of SCS treatment with an alternative form of care, such as a 
surgical procedure or medical management [88,111]. (4) Comparison of one stimulation 
paradigm vs. another using different devices [15,78]. (5) Comparison of the same stimulation 
paradigm using different devices, which might involve alternative implantation techniques 
[2,84,113]. 
The most common study design frameworks are parallel studies or crossover studies.  Superiority 
and non-inferiority hypotheses can be tested in either design. In a parallel study, patients are 
randomized to one treatment or another and followed for a sufficient length of time to support 
the desired clinical interpretation. The main advantage of a parallel study is simplicity of 
execution and interpretation.  Longer observation periods are feasible, compared with a 
crossover study, where, for example, a 3-month observation of each treatment means the patient 
is scheduled to be observed for 6 months. Parallel studies require larger sample sizes than 
crossover studies; in addition, parallel studies do not allow for within-subject comparisons of 
treatments.  In parallel studies of SCS, care must be given to defining the primary analysis 
                                                          
4
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cohort: if patients are randomized to different SCS treatments, then undergo trial stimulation, and 
only the implanted patients are included in the prima y analysis cohort, the populations might no 
longer be equivalent, which violates the intent-to-reat principle (and might invalidate 
conclusions). Comparing one waveform administered by one device with another waveform 
administered by another device will leave uncertain whether any observed advantages were due 
to waveform, device, both, or potential confounders, such as differences in ancillary care or 
programming. An optional crossover at the end of the originally assigned treatment in a parallel 
study phase might yield further information, although careful attention to biases and statistical 
power are needed to support interpretation of such observations. 
In the crossover design, patients are randomized to sequence, where they get two or more 
treatments in a prespecified and balanced order; in incomplete block designs more than two 
treatments are studied but each patient does not receive all treatments.  An advantage of a 
crossover designs is the ability to obtain patients’ direct observations on the differences between 
treatments (e.g., preference). The main disadvantages re the potential for interpretation 
problems due to carry-over effects (the effect of a treatment is influenced by the prvious 
treatment), period effects (the effect of treatments are different in different periods), sequence 
effects (efficacy depends on sequence), and most importantly, treatment-by-period interactions, 
where the relative efficacy of the treatment is different in one period compared with another 
[121,136]. In SCS studies, implanting a single devic  then performing a crossover experiment 
might be the most efficient (least sample size) and most unbiased method for comparing one 
waveform with another. Selecting patients for implantation based on their screening stimulation 
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device with another requires a parallel study to avid having to implant two different devices in 
the same patient. 
Since each study is unique, it is impossible to recmmend specific study designs for every 
scenario. In general, for studies seeking to compare one waveform with another (where 
comparing devices is not relevant), the most efficient approach is implanting a single device and 
comparing waveforms in a crossover design – with care t ken to avoid biases during the 
screening phase, as noted above. If long observation periods are desired, a parallel study might 
be needed so patients are not in the study for too long. For studies seeking to compare different 
devices, or SCS vs. another form of treatment, parallel studies generally make the most sense to 
avoid having to implant two different devices in the same patient and to allow long observation 
periods. Attention to bias and expectation is, as always, critical in such designs to avoid 
uninterpretable results.  When rigorous double-blinding cannot be achieved (and documented), 
such as when comparing a paresthesia-based to a non-paresthesia-based form of stimulation, 
attention to documenting similarity of patient management and expectation management in all 
study groups, as discussed below, becomes critical.  Finally, a study must be feasible: attempting 
the perfect study – for example, sham controlled, when clinicians already accept efficacy – might 
be impossible [93]. 
 
7.  Sources of bias in RCTs of SCS and their mitigation 
Bias refers to a type of measurement error where the ffect of one treatment is exaggerated or 
diminished in comparison with another treatment due to the way the study was designed or 
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is different from the true difference between treatments (thus study results are by definition 
inaccurate). While no study result is perfectly accurate, when biases are significant, the trial 
might lead to a false conclusion: a finding that the reatments are different when they are not 
(false positive) or a finding the treatments are not different when they are (false negative). The 
results of bias are not binary: biases can increase or d crease observed differences between 
treatments whether the primary hypothesis test is statistically significant or not. Put another way, 
a study might claim superiority because of p<0.05, but if the study was biased, the observed 
superiority might not be due not to the study treatment but to how the study was designed or 
conducted.  Bias can produce as large an effect, if not larger, than actual treatment effects [76]. 
Sources of bias and measurement error, emphasizing those relevant to trials on SCS, are listed in 
Table 2. Some examples of biases include allocation bias, observer/expectation bias, and 
asymmetric interactions between treatment groups [116,134]. Expectation and observer biases 
can be conscious or unconscious [77], and the expectation of the investigator can be transmitted 
to the subject consciously, unconsciously, verbally, or non-verbally [13,58]. For that reason, 
“single-blind” studies, where the investigator knows the treatment assignment and the patient in 
theory does not, must be regarded as unblinded.  Unfortu ately, blinding certain types of SCS 
studies can be challenging or impossible. In such cases, options to mitigate expectation/observer 
bias include training of patients and research staff to a balanced and neutral level of expectation 
[166]. Reporting on the effectiveness of blinding, or magnitude of expectation of benefit, might 
help in the interpretation of study results [15,101, 45]. Further, patients in different arms of SCS 
studies must be treated equally, and this equal tretm nt must be documented and reported 
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bias, and in addition raise the issue of whether th latest versions of the respective technologies 
are being compared. 
 
8.  Study Population 
Selecting patients for clinical trials requires a balance between internal validity (the results of the 
experiment can be attributed to the study treatments rather than to extraneous factors), which 
requires patient homogeneity, and external validity (being able to extrapolate the study results to 
a definable population of interest), which requires that the study population resemble the external 
population of interest. Since an invalid trial does not generalize to anybody, internal validity 
must be considered before external validity; for this reason, stringent inclusion/exclusion criteria, 
and sufficiently detailed subject characterization  determine who was studied and which 
subject characteristics might predict response, are required in clinical trials [44]. Subject 
eligibility for SCS trials progresses in stages: initial screening for general and disease-specific 
criteria determines whether patients are eligible to proceed to randomization and a temporary 
trial of SCS (in either order), and the screening trial itself, when utilized, determines eligibility 
for implantation and continued observation. 
General eligibility criteria typically include a clear and confirmed diagnosis and pain type, stable 
underlying pain pattern, minimum and maximum pain intensity and duration, minimal 
psychosocial vulnerabilities, ability to cope with technology, failure of more conservative 
treatments, and stable or absent concomitant analgesics [32]. Patients can be characterized using 
body maps [9], where areas of pain and its intensity can be captured; bedside sensory testing for 
sensory phenotyping [33], quantitative sensory testing, and other neurophysiologic techniques 
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carefully considered, including co-morbidities and factors that influence SCS outcomes. For 
example, in failed back surgery syndrome, patients might have variable contributions of 
neuropathic pain versus nociceptive pain. Certain types of neuropathic pain, especially those 
with predominant large fiber damage and relatively preserved nociceptor function, might be 
more responsive to SCS than nociceptive pain [88]. Using tools to determine the extent to which 
the patients’ pain is neuropathic might be helpful [97]; however, the predictive validity of these 
tools for response to treatment is not yet established [51,98]. Importantly, evaluating whether 
patients meet eligibility criteria should not be left to a simple checklist but should instead depend 
upon collection of primary data, so the investigator’s determination that a patient met eligibility 
criteria can be verified. 
The rate of conversion of trial stimulation to permanent implants varies widely among centers for 
unclear reasons – potential explanations include variability in characterizing patients, the 
duration of trials, a lack of blinding and other contr ls for nonspecific treatment effects, and 
measurement error in capturing clinical data [69]. Thus, trial stimulation procedures should be 
standardized and well-documented. Alternatively, since the evidence for the predictive value of 
SCS trials is scant and evolving, consideration maybe given to skipping trial stimulation [35]. 
The concept of enrichment [44] applies in several different ways to SCS RCTs and can be 
considered in terms of pre-randomization vs. post-randomization enrichment. Pre-randomization 
enrichment can be accomplished by performing a screening trial then randomizing responders to 
different treatments, e.g., waveforms or devices. Enrichment procedures, however, might bias the 
study in favor of one treatment arm over another. Fo  example, if enrichment is done with 
waveform A, and responders are then randomized to waveform A vs. waveform B, the study is 





8 8Copyright  by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2021
19 
 
issue.  For example, the PROCO study first enriched based on response to low-frequency 
stimulation that evoked paresthesia, then, after implantation, required a response to paresthesia-
free stimulation [146]; this approach raises the issue of pre- vs. post-randomization enrichment. 
Post-randomization enrichment introduces analysis and interpretation issues and does not meet 
criteria for a valid enriched enrollment design [44]. For example, patients can be randomized to 
device A or device B, undergo a trial of the device to which they were assigned, and if they 
experience an initial response, continue onto implantation and follow-up.  While reflective of 
clinical reasoning, such studies require careful analysis and interpretation, since the analysis 
cohorts are no longer the originally randomized groups, violating the ITT principle and 
potentially introducing bias. 
 
9.  Outcome assessment 
Planning to assess clinical outcomes requires reviewing the purpose of the study, considering 
information different stakeholders might be interested in (patients, families, healthcare providers, 
regulators, payers, employers), and crafting an “endpoint model” [124,162].  The endpoint model 
begins with establishing the study objectives (prima y, secondary, exploratory), which are 
clinical concepts (or domains) to be evaluated in the study. For example, an objective could be to 
evaluate the effectiveness on pain intensity of device A vs. device B. A clinical outcome 
assessment (also called instrument or measure) refers to a tool that will be used to measure this 
clinical concept (e.g., a 0-10 numerical rating scale for average pain over the past 24 hours, with 
0=no pain and 10=worst pain imaginable). The endpoint refers to how the assessments will be 
captured to address the objective. For example, an ndpoint could be the average of 7 
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with an electronic diary. The endpoint model is a tabular array of each study objective, 
assessment, and endpoint, ensuring that each objective is supported by appropriate assessments 
and endpoints and, conversely, that each assessment and endpoint is mapped onto an objective.  
Assessments that do not map onto a specific study objective, such as baseline demographic 
assessments, should be categorized as such. 
Outcome assessments can be clinical (COAs) or nonclinical (biomarkers) [162]. COAs include 
any assessment that can be influenced by human choices, judgment, or motivation. Biomarkers, 
such as imaging, heart rate variability, and other physiological assessments, are less likely to be 
linked to patient influences, but their clinical reevance requires demonstration of a link to a 
COA. COAs must be well-defined and possess adequate measurement properties to demonstrate 
the benefits of treatment. Types of COAs include patient-reported, clinician-reported, observer-
reported, and performance outcomes [120,162]. Performance outcomes can be clinician-rated or 
supervised (e.g., staircase maneuver in osteoarthritis of the knee) [152] or unsupervised 
“objective” measures (e.g., actigraphy) [147]. Measuring only physical activity parameters, such 
as walking distance, speed of walking or time spent r sting, might be misleading. Long-term 
recordings of detailed physical activity measurement using multiple body sensors suggest that 
the temporal dynamics of activity patterns are important, and their complexity decreased in 
chronic pain [118,119]. 
Table 3A presents a list of recommended domains and measures originally recommended by 
IMMPACT for chronic pain studies [28,155], later suggested by patients in an IMMPACT 
survey [156], additional ones commonly used in chronic pain studies, and several specifically 
recommended for SCS studies. Different painful disorders for which SCS may be studied will 
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for studies in critical limb ischemia or allodynia in studies of neuropathic pain. In addition to the 
listed measures, PROMIS® (Patient-Reported Outcomes Measurement Information System) is a 
comprehensive set of measures of physical, mental, and social health developed with funding by 
the US National Institutes of Health that may be usd in clinical trials [131]. 
Responder analyses (proportion of patients achieving a pre-defined outcome) may also be 
considered for clinical interpretability, statistical, or regulatory reasons.  The United States Food 
and Drug Administration (FDA), for example, evaluates responder analyses and composite 
endpoints to help reveal the overall effect of an intervention on an individual basis as well as 
overall clinical benefit. The FDA recommends additional discussion of the pros and cons of a 
responder analysis vs. mean analysis for assessing populations vs. individuals, across a variety of 
trial designs.  Single outcome responder indices refer to prespecified cutoffs on a single measure 
(e.g., decreased pain intensity by 30% or 50%).  Composite measures combine different patient 
assessment measures into a single determinant of whether the patient has “responded” to 
treatment; for example, a patient may be considered a responder if their pain decreases by at least 
50% and they do not increase use of concomitant analgesics.  Composite responder indices might 
be more or less statistically responsive than continuous or single outcome responder indices, so 
caution must be exercised and decisions preferably based on analyses of previous clinical trials. 
Depending on the goals of the study and the needs of consumers of the data, various elements 
can be considered for composite measures, such as pain, analgesic consumption, function, 
tolerability, completer status, and global satisfaction. Specific disorders might suggest specific 
elements of a composite, such as with angina or limb ischemia. The composite measure should 
be a measure of a specific clinical concept and not a complex of different clinical concepts, 
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statistically efficient endpoint should be selected for the primary endpoint in order to experiment 
on the fewest subjects possible to achieve the study objective. Less efficient endpoints needed 
for clinical interpretation can be relegated to secondary endpoints, recognizing that the study will 
be underpowered for those results. 
 
10.  Adverse events 
SCS complications occur in 23-55% of patients, must be addressed early, and can be reduced 
[4,62,102,158]. The rate of reported AEs depends on the type of study (retrospective, 
prospective), duration of follow-up, method of capturing and reporting AEs, and other factors. 
AEs can be divided into biological and technical categories. Biological complications refer to 
adverse consequences to the body, such as infection, hematoma, or wound dehiscence; technical 
complications refer to device hardware problems, including lead migration, lead fracture, and 
implanted pulse generator (IPG) malfunction, which might also have medical consequences; and 
uncomfortable paresthesia [62,86] (Table 3A). Infections are reported in 3-10% of studies 
[20,62,158] and most commonly occur in the IPG pocket; nearly all infected devices are partly or 
completely removed [50]. Reporting should distinguish between superficial and deep surgical 
site infections [20]. Surgical device explantation due to an AE is another key safety outcome and 
can be presented as a survival curve (median time to explantation) or as the proportion explanted 
over a fixed time period [4]. Explantation can be performed for other reasons as well (e.g., the 
patient no longer has pain, the device is no longer eff ctive), which should also be reported. 
Complications can be characterized by whether they require surgery, whether the device was 
partially or completely explanted, time to occurrenc  (which differs among different 





8 8Copyright  by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2021
23 
 
Study reports should include AEs collected by a standard and explicit method (e.g., a non-
leading question, for example, “have you had any issue  since your last visit”), and should 
identify serious AEs, AEs related to the device, AEs of special interest (which may be agreed 
between sponsor and health authority and may be assessed by a prospective clinician 
questionnaire), and unanticipated AEs related to the device. AEs must be collected in a similar 
fashion for all participants in the study according to post market surveillance guidelines within 
their respective country/state.  If a novel SCS is being trialed; additional measures may be 
required for monitoring AEs by the competent authori y at the time of clinical investigation 
approval. Definitions of AEs and related terms are available in the ISO/DIS 14155 guidance on 
“Clinical investigation of medical devices for human subjects – Good clinical practice” [73].  
AEs and risks should also be evaluated in the context of benefit in any given study. This risk 
benefit ratio is also a factor in the review of a device for marketing authorization in several 
countries and regions. 
 
11.  Study execution 
Any clinical trial protocol can be ruined by poor study conduct. Study conduct begins with 
crafting a simple and doable protocol, then proceeds to site selection. For SCS studies, 
capabilities required beyond general clinical research capabilities include skill in the 
investigational procedure [64], skill in the comparator procedure(s), skill in providing clinical 
care for patients undergoing SCS, which might include psychological or rehabilitative support 
and the management of complications, skill in performing diagnostic and outcome assessment, 
and a quality system focused on SCS. Capturing and potentially controlling for the level of 
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provided in Supplemental Table 1 (available at http://links.lww.com/PAIN/B272). In multicenter 
trials, standardization of implementation across centers can be a significant challenge, and 
seemingly minor differences can introduce variability of outcomes, reducing the opportunity to 
establish (or falsify) efficacy of any treatment approach. 
Patient selection is a challenging issue in any therap utic area; in SCS studies additional 
considerations apply. Clinical research ethics requi  equipoise, which can be achieved by 
providing balanced information in all available sources, including company websites, internet 
postings about the clinical trial, informed consent documents, patient education materials, and 
verbal descriptions and body language [76,81]. Interactions should be scripted to the extent 
possible to minimize the risk of bias. E-consent might provide a better method for standardizing 
consent procedures compared with traditional informed consent interactions [59]. 
Ethical issues include making implantation or earlir access to treatment conditional upon 
research participation, which is a form of coercion. All patient recruitment materials should be 
made available in clinical study reports and, to the extent possible, in publications. Consideration 
should be given to measuring and reporting subject expectation of benefit at the time of 
randomization. Once the job of recruitment is finished, the job of retention begins. Attention 
should be paid to assisting patients in overcoming the burdens of clinical trial participation, 
including compensation, transportation support, reminders and communication, and positive 
feedback (but not by inflating expectation of benefit). 
Training participants in clinical trials to perform their roles to specified standards has become 
“best practice” in clinical trials and is specifically called out in regulatory guidelines addressing 
quality control issues [48,70]. Participants are rar ly told that the success of any clinical trial 
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research demonstrates that this is the case [31,32,130]. At a minimum, participants must be 
educated about their responsibilities under the protocol, such as adherence to treatment (since 
adherence to the SCS regimen is necessary for assessment of efficacy), entering data, blinding 
procedures, use of concomitant and rescue medications, avoiding prohibited treatments, and 
reporting AEs. In addition, participants should be trained on reporting their symptoms accurately 
and on appropriate expectations of benefit (often called “placebo response reduction training”) 
[150]. 
In addition to standard training (Good Clinical Practice, protocol), investigators should be 
thoroughly trained on all key study procedures where variability might be problematic, and have 
competence documented; performance should be monitored quantitatively throughout the study. 
Patient behavior that has an impact on the integrity of study results must be documented. 
Accurate documentation of adherence to the prescribed SCS regimen might be obtainable from 
the devices themselves. Reliable documentation of rescue medication adherence requires 
electronic methods (e.g., smart packaging, although this does not document “pill to mouth” but 
rather “pill to hand”). Pill counts and in-clinic self-report of recalled rescue medication 
consumption are not accurate measures [6,8]). Daily electronic capture of rescue medication 
consumption has been increasingly used to capture rescue medication consumption and might be 
accurate; however, we are unaware of any publications documenting the accuracy of this 
method. 
Patients frequently take pain medications for non-index pain syndromes, such as headache or 
sprains. These may be classified as “concomitant analgesics taken for non-index pain,” and since 
patients often fail to disclose these (because of po r recall, inconsistent querying methods, or 
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patients in a non-judgmental manner at each clinic visit about any pain medication taken since 
the last visit and to capture the reason for taking each one.  Pain medication taken for a new pain 
syndrome, or worsening of a stable pain syndrome, would generally be reportable as an AE. 
Home paper diaries for capturing clinical outcomes as essments (e.g., pain) are not reliable 
[142]; electronic data capture methods are required for assessments that are not completed in 
clinic [74,75]. 
Patients should receive accurate and complete communication about what happens after the 
completion of the study. Factors to consider are the disposition of the device after the study is 
complete, coverage of costs during and after the study, and documentation of communication of 
these issues and other issues of concern to patients about events after study completion. 
 
12.  Data analysis, interpretation, and reporting 
Although standards for data analysis, interpretation, and reporting have been much discussed in 
the literature, the review of SCS studies summarized above suggests that several of these 
standards are frequently not followed. Several salient points will be discussed herein without an 
attempt to cover all potential issues. One concern is controlling Type I error (the probability of a 
false positive result). Simply performing multiple comparisons can cause a Type 1 error: the 
more statistical tests are performed, the more likely one will reach the significance threshold by 
chance and the study be interpreted as “positive.” Sponsors must therefore prespecify a primary 
endpoint, label other endpoints as secondary, and specify an endpoint model, including details of 
analysis methods. If multiple primary endpoints are chosen, then methods for handling 
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Basic data integrity – that the data provided by the patient is the same as that being analyzed in 
the clinical dataset – is a fundamental requirement of research sponsors.  Missing data, i.e. data 
not provided by the subject or site, undermine the int rpretability of clinical trials, and methods 
for handling it must be prespecified. The method of imputation depends on choice of estimand—
or the population and endpoint that reflects the sci ntific question of interest [70], which might 
differ for different analyses of the same clinical trial dataset. For example, if the estimand is the 
efficacy of a treatment assuming that participants re able to use the treatment, missing data 
could be imputed using a multiple imputation method that assigns missing outcome values using 
the characteristics of the participants whose data are missing, the outcomes of the other 
participants in the group to which the participant was randomized, and the participant’s outcome 
score at the time of discontinuation. If, however, the estimand is the efficacy of the treatment in 
the overall population, including those who have an adverse reaction to the treatment, missing 
data could be imputed using a multiple imputation method similar to the one described above if a 
participant withdrew for any reason other than an AE; but if a participant withdrew due to an AE, 
then the missing data could be imputed using the data from participants in the control group. The 
rationale for this method, which is called control-based imputation, is that if a participant cannot 
use the treatment, their outcomes would still be aff cted by the non-intervention aspects of the 
trial (e.g., attention, expectation), but they should not be counted as having received benefit of 
the treatment, even if they did experience some efficacy benefit before they had to discontinue 
due to an AE. Different methods to handle missing data make different assumptions regarding 
the patterns of missing data. These assumptions, includi g missing completely at random, 
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Another source of widespread confusion is that of clinical meaningfulness. It is critically 
important to differentiate WITHIN-PATIENT clinical meaningfulness from BETWEEN-
GROUP meaningfulness [25,30]. Within-patient clinical meaningfulness refers to the degree of 
change in a measure reported by individual patients that will be rated by patients, on average, as 
meaningful to them. This is useful for defining “responders” to treatment in a clinical trial. The 
most commonly used cutoff is 30% pain reduction, although arguments can be made for cutoffs 
as low as 20% or as high as 80% [41,83]. Reporting a cumulative distribution function of 
response is useful in all studies, since readers can ex mine the between-group difference at any 
response cutoff [41]. Note that this is an average – some patients are satisfied with smaller 
improvements, and others require larger improvements. Within-patient clinical meaningfulness is 
an entirely different matter than between-group clini al meaningfulness, which refers to the 
degree of difference in an endpoint between the treatm nt and control groups that indicates that 
the treatment provided a clinically meaningful benefit in that study sample [26,30]. There is no 
consensus on between-group differences that are clinical y meaningful for all treatments, nor can 
there be, since this depends on many factors including risk of treatment, inconvenience, 
availability of alternatives, etc., and will differ for different audiences. For example, a modest 
improvement in pain intensity reduction over placebo might be clinically meaningful for a new 
treatment that is associated with trivial risks; alternatively, a large benefit in pain reduction will 
be needed for the benefits of a riskier treatment to be considered meaningful. 
Interpretation of a clinical study is rarely as straightforward as “positive” or “negative” despite 
the inordinate attention paid to the p=0.05 boundary. As famously noted by Jacob Cohen, “the 
primary product of a research inquiry is one or more measures of effect size, not p-values” 
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pattern of effect sizes on secondary endpoints, then t ir p-values, without losing sight of safety 
and how it was assessed, with the ultimate goal of understanding the overall risk-benefit balance 
of treatment compared with control. Confidence intervals (CIs) can inform interpretation of 
statistically significant or non-significant superiority trials [53]. In a case where the primary 
endpoint p-value is greater than 0.05, CIs can further determine whether the trial failed to 
demonstrate superiority (i.e., superiority is still possible, but the trial was inconclusive) or the 
data are consistent with true lack of superiority. 
Reporting of clinical trials in general, and trials of SCS in particular, has been problematic, due 
to inadequate reporting of primary data, failure to adhere to reporting standards, and 
discrepancies between documents submitted to regulatory uthorities, published papers, and 
marketing materials. General reporting standards are available from the CONSORT group [105]. 
A pain-specific supplement to CONSORT is also available from ACTTION [52], as well as a 
discussion of issues that arise in the reporting of cr ssover trials [54]. A guideline for describing 
complex interventions in clinical trial reports has been published [66]. Additional 
recommendations for the reporting of SCS trials for pain are provided in Table 3A and Table 3B. 
A final consideration is what claims should be possible from a given study; while the term 
“claims” is usually invoked in the regulatory context with respect to product labeling, the same 
concept applies in the clinical context with respect to what recommendations for use of the 
product are justified based on the study results. For example, a specific study might justify a 
“claim” for temporary use in the treatment of chronic pain or long-term use depending on study 
design features. Studies should be designed to anticipate an end result that would indicate what 
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13.  Economic outcomes and cost-effectiveness analyses 
Many SCS trials are designed to characterize primary efficacy and safety, frequently for 
regulatory approval. If payers do not pay for the trea ment, however, the studies designed for 
regulatory approval become pointless, which exposes human subjects to risks for no social 
benefit. 
Types of data of interest to payers vary by region. For example, in the United States, the average 
patient changes health coverage every three years; thus, health economics measures that involve 
break-even points beyond three years might not be atractive to third-party payers. Depending on 
the economic question of interest, endpoints can be add d to primary efficacy/safety studies to 
provide further insight. For questions of interest requiring long-term observation or access to 
claims data, standard RCTs might need to be augmented by studies designed specifically to 
address those issues. 
Most studies primarily focused on establishing safety and efficacy are relatively short-term, with 
a median duration of post-randomization follow-up of 12 weeks, as noted above. Health 
economics endpoints that can be incorporated into such trials include work-related endpoints 
(e.g., absenteeism, presenteeism, productivity), healt care use and associated costs, and health-
related quality of life endpoints (using, for example, the EQ5-D or the SF-6D), which can be 
converted into quality-adjusted life years (QALYs). The most common health economic 
construct of interest is cost-effectiveness, which is typically measured by difference in costs and 
outcomes between the intervention and comparator. Cost-utility studies have also been 
conducted in SCS and report results in terms of QALYs. Endpoints with economic implications 
that might require dedicated, often post-marketing studies, include long-term safety, incidence of 





8 8Copyright  by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2021
31 
 
data, such as costs of care not readily captured in an efficacy/safety RCT (emergency department 
visits, comprehensive medication costs, behavioral he th costs, hospitalizations, etc.). 
Despite the studies demonstrating cost effectiveness [10,87,114,139,144], with the general rise in 
healthcare costs the reimbursement climate for SCS has become increasingly challenging. Payers 
have observed that most studies designed to support regulatory approval are non-inferiority in 
design, without placebo controls, and without cost effectiveness data, and accordingly question 
the value of such studies. Available cost effectiveness analyses, even though performed 
rigorously and yielding supportive results, are dependent on data from RCTs of SCS that, as 
described above, are typically prone to bias; however, the National Institute of Health and Care 
Excellence (NICE) in 2008 recommended SCS for patients with neuropathic pain based on 
modelling of an acceptable cost per QALY (<£20,000/QALY) [108]. Going forward, to be 
persuasive to payers, cost effectiveness studies need to use data based on well-designed RCTs 
that have appropriately controlled for bias, with relevant outcome assessments and sufficient 
duration of follow-up. Thus, sponsors should consider performing trials that are not only 
sufficiently rigorous to convince regulators for approval but also can robustly demonstrate to 
payers the value of SCS, using the recommendations provided in this article. 
 
14.  Special issues in RCTs of SCS, including sham stimulation and programming 
comparisons 
The need for a trained individual to perform skillful programming of the device on a repeated 
basis in order to maximize the benefit of treatment creates unique challenges in SCS studies. 
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clinical staff, which creates the opportunity for inconsistent interactions and bias, since attention, 
number of visits, time spent during visits, and enthusiasm of health care providers are all likely 
to increase placebo responses [159]. Thus, if an RCT of SCS in which the number, length, and 
content of programming interactions is not standardized and balanced between groups 
demonstrates superiority of one group over another,  superiority cannot necessarily be 
attributed to the SCS treatment. Information about programming in SCS study reports is often 
absent, scant, or confusing, making it difficult for the reader to evaluate potential bias. 
We recommend that a standardized approach to programming be devised and presented in the 
Methods section of reports and publications (e.g., [15,90]). Standardized approaches will need to 
allow sufficient flexibility to meet individual patients’ needs.  Interactions should be scripted and 
monitored.  Industry should provide best practice programming approaches to inform the 
protocol. Ideally, industry personnel should not perform programming; exceptions should be 
justified and monitored. Standards for the qualifications of individuals at the sites who perform 
programming should be established and documented. Outcomes of programming, including 
programming results (e.g., mean, ranges, and mode valu s for the programming parameters), 
whether scheduled or non-scheduled, duration of session , who was involved, any deviations 
from the initial planned programming algorithm, and costs (for studies including economic data) 
should be included in the results. Reprogramming as a treatment for an adverse event should be 
captured formally as an AE. 
Double-blinding can be challenging in SCS studies, especially when comparing low-frequency 
stimulation with either placebo or non-paresthesia-based stimulation. Investigators have 
attempted to improve the integrity of blinding by delivering ultra-short duration paresthesia or 
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these tactics might have a neuromodulatory effect and, therefore, might not act as pure placebo 
but rather a low dose of treatment [167]. (It may equally be argued, however, that if ultra-short 
stimulation (minutes/day) has a neuromodulatory effect equivalent to traditional SCS, then it 
should be used in preference to traditional stimulation given the potential savings in battery life.) 
Another potential source of unblinding is the patients’ interaction with their handheld SCS 
controller, due to subjects accessing information about their stimulus intensity, program 
parameters, response from their SCS IPG, or the charge status of their IPG, especially in 
crossover designs: a sudden drop (or increase) in rcha ging requirements might lead subjects to 
guess that they have entered the placebo (or active) treatment period. Some investigators have 
programmed IPGs to leak current so as to require recharging at similar intervals to the active 
study arm [1,121]. Investigators, therefore, need to specify the type of IPG used in a study 
(rechargeable vs. non-rechargeable) as well as any teps taken to control related sources of 
unblinding. 
The complexity of these blinding-related issues makes it impossible, and undesirable, to 
prescribe one-size-fits-all approaches. However, investigators should perform double-blind 
studies whenever possible (exceptions should be strenuously justified and the lower level of 
evidence of such studies acknowledged); use blinded assessors in any studies that are not fully 
blinded; explain in the Methods section how potential threats to blinding were handled; and 
perform and report assessments of patient expectation, effectiveness of blinding, or the 
equivalent. Claims in study reports that double-blinding was not possible are offset by reports of 
success with double-blinding in single- and multicenter studies of SCS and similar devices 
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replicated when the same treatments were compared under blinded conditions [15,78], further 
supporting the importance of maximizing blinding in SCS trials. 
A critical research question is whether one waveform is more effective than another. Since in 
theory any device can deliver any waveform, studies esigned to compare waveforms should be 
possible with a single device. Yet, with a few recent xceptions (e.g. [146]), some manufacturers 
have been reluctant to allow their devices to be programmed for this purpose for proprietary 
reasons. Using different devices to compare different waveforms might introduce confounding 
and increase patient risk.  Similar issues apply to programming current leaks to maintain 
blinding. The ethics of manufacturers’ positions on features of their devices requires careful 
consideration to enhance technical programming sharing with investigators and achieve full 
transparency. 
 
15.  Conclusions and Recommendations 
The last half century has been characterized by important advances in device technology and the 
clinical research methods used to study them. Yet the evidence base for the efficacy and safety of 
SCS for pain still consists largely of clinical trials that, even when RCTs, are sufficiently lacking 
in rigor that conclusions about the efficacy of SCS for chronic pain, or the superiority of one 
waveform or device over another, while firmly believed by many clinicians, remains below 
current evidentiary standards. The main inadequacies of SCS RCTs conducted to date include the 
use of non-inferiority designs without internal demonstrations of assay sensitivity; failure to 
control and transparently report how important sources of bias, such as double-blinding, 
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information that lead to unbalanced expectation were addressed; and unclear or inconsistent 
safety reporting. Our hope is that the recommendations contained herein will lead to the 
generation of higher quality data to support decision  of patients, clinicians, regulators, and 
reimbursement authorities on the utility of SCS in treatment. Based on the review presented, we 
recommend that the features listed in Tables 3A and 3B and the considerations for management 
of bias and measurement error presented in Table 2 e considered in the design of all future 
studies evaluating the efficacy and effectiveness of SCS for chronic pain. 
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Figure Legends 
Figure 1A.  Types of generators.  All SCS systems include an external, portable (and therefore 
battery powered) transmitter which emits (and in some cases receives) a wireless or 
radiofrequency signal providing telemetry and/or power. The implanted generator may contain a 
battery (which may be rechargeable), allowing autonomous operation, or it may operate on 
external power alone. 
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Figure 2.  Interpretation of non-inferiority studiesa.  The letters indicate the point estimate of 
efficacy, and the error bars the 95% confidence intrvals in these hypothetical trials.  The vertical 
line labeled “0” indicates the point of zero difference between “new treatment” and comparator 
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Table 1.  Types of spinal cord stimulation 
Name Frequency Pulse 
Width 
Amplitude Waveform Comment 
Low 
frequency 





manually adjustable output. Also 
called “tonic”, although this 
technically describes any 
waveform with constant evenly 
spaced pulses. 
Burst Passive charge 
recovery: 
40 Hz intra-
bursts of 5 




Up to 80Hz intra 
- bursts of 3 to 7 
























Several types of burst stimulation, 
some with passive, others active 
charge recovery 








Fixed-output, typically below 
paresthesia threshold. 
High charge 300-1200 Hz 150-800 µs 1-5 mA 
 
Fixed-output, typically below 
paresthesia threshold. 
Minimal time between pulses 














Stimulation amplitude adjusted 
based on physiologic response to 
stimulation, e.g., evoked 
compound action potentials 
(ECAPs), to maintain a target 
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10 – 1000 Hz 100 – 350 
µs 
1-5 mA  Stimulation amplitude on each 
contact adjusted to preferentially 
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Table 2.  Sources of bias and measurement error in RCTs and their mitigation 
Source of Error Description Mitigation Options 
Allocation bias Investigators choose which subjects go 
in which groups 
● Randomization [133] 
● Concealment of assignments before patient 
selection 
Expectation bias Subjects report the response they 
expect (e.g., pain relief) 
Research staff expectation is 
transmitted to patients consciously or 
unconsciously 
● Double blinding [133] 
● Placebo controls 
● Neutral expectation training of researchers and 
subjects [166] 
● Balanced information in all groups [76] 
Unbalanced 
randomization* 
Treatment groups differ by prognostic 
factors or treatment effect modifiers 
● Stratified randomization [83] 
● Adjust analyses for potential confounding factors 
Observer bias Those who observe the treatment effect 
report their desired outcome 
● Double blinding 
● Neutral expectation training of observers [58] 
Unbalanced 
ancillary treatment 
Patients in one group get more 
attention, supplemental treatments, 
visits, psychological support, etc. 
● Double-blinding 
● Standardized and documented ancillary treatment 
and interactions (e.g. programming) 
Patient selection or characterization 
Inaccurate diagnosis Patient does not have the disease being 
studied 
● Central review of diagnostic assessment [97] 
● Investigator training [97] 




Patients might not be able to report 
pain accurately  
Inaccurate pain reporters are also 
placebo responders 
● Accurate pain reporting training [149,150] 
● Exclude patients with excess variability of clinical or 
experimental pain [31,32,42,140,148] 
Placebo responders 
 
Preferential placebo responders have 
higher than average responses to 
placebo but not to active treatment 
● Select internally focused patients [31,32,148] 
● Neutralize expectation [32,151,166] 
Baseline score 
inflation 
Subjects/investigators might inflate 
baseline scores to meet enrollment 
criteria 
● Mask entry requirements 
● Use different measures for the primary endpoint 
and for inclusion 




Pain that is highly variable or destined 
to resolve during the study decreases 
assay sensitivity 
● Enroll patients with a history of at least 12 months 
of moderate to severe chronic pain 
● Minimum pain intensity of 4–5/10 





Patients with psychological 
comorbidities or substance abuse report 
pain less reliably and might be less 
compliant with study procedures 
● Exclude such patients based on established 
validated assessments (including urine drug 





Studying mixed phenotypes might result 
in failed studies when the treatment is 
effective in a specific phenotype 
● Phenotype all subjects at baseline and evaluate 
efficacy by phenotype [33,119] 
Duplicate subjects Patients often deceitfully enroll in the 
same study at multiple sites or in 
multiple studies, putting themselves 
and the study at risk 




Patients are often unable to supply all 
relevant information about past or 
● Consider methods to import prescription 
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current medical history and 
pharmacologic and non-pharmacologic 
treatments 
data for enrolled subjects 




Measures must not only be valid and 
reliable, but also responsive to 
treatment differences 
● Choose the most responsive measure that is valid 
for the target concept 
● Prioritize disease-specific over generic measures 
● Consider developing a new measure if no suitable 
measures are available or if there is reason to 
believe that a new measure would be substantially 






E-diary compliance is poor in many 
studies 
Missing data in general must be 
minimized 
● Automated reminders; alerts to coordinators for 
missed entries; calls from coordinators to subjects 
after missed entries; real-time central monitoring 
● Back-up in-clinic assessments of the primary 
endpoint 
● Avoid paper diaries [142] 
Adherence to study treatments 
Failing to measure 
adherence (to study 
or rescue 
treatment) 
accurately or to 
achieve adherence 
Variable and poorly documented 
adherence to SCS regimen or rescue 
medications 
● Document prescribed SCS regimen and adherence 
to it 
● Standardize and provide rescue meds; measure 
adherence electronically 
● Real-time central monitoring of adherence.  
● Adherence promotion strategy [6,8] 
Confounding by subject 
Subjects failing to 
follow protocol 
Subjects need to follow the protocol, 
particularly medication adherence, diary 
compliance, accurate symptom 
reporting, and stable regimens of non-
study treatment (e.g., physical therapy) 
● Perform a training needs assessment based on risks 
to data quality [48] 





No new physical or psychological 
interventions should begin during 
studies. Patients should maintain  
unchanged physical and psychological 
regimens 
● Provide structured guidance to subjects about 
physical and psychological therapeutics; consider 
structured support 
● Capture changes in physical and psychological 
regimens using questionnaires; consider objective 
measures such as actigraphy  [154] 




Heterogeneity in health care systems, 
language, culture, availability of 
treatment, etc., introduces error 
● Minimize the number of sites; invest in pre-study 
recruitment activities to maximize the number of 
patients/site 
● Minimize heterogeneity in sites and regions 
 
Variability in study 
conduct by sites 
Sites implement protocols in varying 
ways that might be difficult to predict, 
describe, or understand 
● Perform a training needs assessment based on risks 
to data quality  [48] 
● Follow principles of validated training (Katz N, 
unpublished, 2020) 
● Central statistical monitoring and intervention 
[48,70] (and Katz N, unpublished, 2020) 
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Table 3A.  Recommendations for randomized controlled trials of spinal cord stimulation for chronic 
pain: Outcome measures and reporting 
Outcome Evaluation   
Endpoint model Describe the endpoint model in the protocol; have clear and 
aligned objectives, assessments, and endpoints 
[162] 
Primary endpoint  
 
Must be prespecified 
Adjust for multiplicity 
Specify missing data imputation method  
[25,56,156] 
Secondary endpoints Key secondary endpoints will more likely show differentiation 
between treatments if they also meet minimum baseline 
severity criteria 
 
Adverse events Prespecify the method for ascertaining AEs (e.g., open-ended, 
spontaneous, checklists, scripts) 
[80,141] 






• 0-10 numerical rating scaleb 
[27,31] 
 Physical Function 
• Brief Pain Inventory Interference Items 
• Oswestry Disability Inventory 
• Roland-Morris Disability Questionnaire 
• WOMAC Function subscale 
[28,157] 
 Emotional Functioning 
• Beck Depression Inventory 
• Hospital Anxiety and Depression Scale 
• Profile of Mood States 
[28,157] 
 Global Improvement or Satisfaction 
• Patient Global Impression of Change 
• Patient Satisfaction Scale 
• Would you do this again? 
[28] 
 Concomitant and Rescue Medications 
• Careful capture in-clinic of concomitant analgesic 
medication including dose, frequency, and reason for use 
(i.e. index or non-index pain) 
• Rescue medication use by electronic methods 
• Opioid consumption 
[6,28] 
 Patient Disposition 
• Adherence to treatment regimen: SCS and any additional 
treatments 
• Reason for early termination 
[155] 
 Sleep and Fatigue 
• MOS Sleep Scale 
• Pittsburgh Sleep Quality Index 
• Multidimensional Fatigue Inventory 
[28,157] 
 Health-Related Quality of Life 
• EQ5-D 
• SF-36 
• Quality-Adjusted Life Years (QALYs) 
[28,157] 
 Cost-effectiveness 
• Dollars per QALY 
[126] 
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• Country-specific health and social care costs 
 Work status 
• Work Productivity and Activity Impairment Questionnaire 
• Workplace Activity Limitations Scale 
• Work Limitations Questionnaire 
[157] 
 Patient preference (for crossover studies) 
• Preference scale 
[63] 
 Abuse-related events 
• MADDERS 
[153] 
 Opioid side effects 
• Opioid Side Effects Scale 
[40] 
 SCS-specific measures 
• Device survival/revision-free survival 
• Durability of analgesia 
• Adherence to SCS regimen (e.g., hours use/day) 
• Recharging burden (recharge interval, time required for 
recharge) 






Prospective monitoring for: 
• Infection (superficial, deep) 
• Cerebrospinal fluid leak 
• Hematoma 
• Stimulator pocket fluid collection 
• Wound dehiscence 
• Skin erosion 
• Allergic reaction 
• Lead migration/breakage 
• Hardware malfunction 
• Battery failure 
• Loose connection 
• Implantable pulse generator migration/discomfort 
• Dysesthesia 
• Device explantation (and reason) 





Methods • Patient characteristics and eligibility 
o Neuropathic pain assessment 
o Sensory phenotyping 
o Literacy and numeracy 
o Ability to report pain accurately 
o Level of expectation 
 
 • Blinding 
o How it is maintained and documented 
o Patient access to controllers and recharging 
 
 • Expectation 
o How balanced expectations are created and 
monitored 
o Information provided to subjects and staff 
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o Prescribed SCS regimen, allowed concomitant and 
rescue medication 
o How adherence will be measured and 
documented 
 • Analysis  
o Primary estimand 
o Complete primary endpoint including primary 
analysis cohort, clinical outcome assessment, 
analysis method, handling of missing data 
o All secondary endpoints (secondary endpoints can 
be considered for claims if appropriate 
procedures for handling multiple endpoints are 
implemented) 
o Confidence intervals with interpretation 
o Handling of multiplicity for studies with multiple 
primary endpoints 
o Sample size calculation and supporting 
assumptions 
[56] 
Results Follow applicable reporting guidelines:  
 CONSORT statement [106] 
 Pain-specific supplement to CONSORT [52] 
 Recommendations for reporting crossover studies [54] 
 Recommendations for describing complex interventions [66] 
 Recommendations for reporting cost-effectiveness studies [132] 
 SCS-specific reporting recommendations:  
 Programming details  
 Position of cathode, method of placement (e.g. paresthesia 
mapping), details of trial stimulation 
 
 Description of risk-based quality management activity  
a.  Recommendations are not meant to be prescriptive; measures are provided as examples and should be 
evaluated based on the study context.  Not all domains or measures will be appropriate for all studies.  Review of 
the psychometric properties of all measures should be performed for each study. 
b.  Location should be specified, e.g., index vs. non-index pain location 
c.  Note that some complications are associated with AEs and others are not. Ascertainment of specified 
complications should be prospective whether associated with AEs or not. 






8 8Copyright  by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2021
Table 3B.  Recommendations for randomized controlled trials of spinal cord stimulation for chronic 
pain: Study design and Conduct* 
Issue Recommendation References 
Overall design   
Mechanistic studies Study mechanisms of action and biomarkers in concert with 
clinical outcomes whenever possible 
[11,93,96] 
Non-inferiority designs Non-inferiority designs, if used at all, should incorporate 
internal demonstration of assay sensitivity (e.g., a successful 
superiority test to placebo control) 
[47] 
Blinding Double-blind whenever possible; claims that blinding was not 
possible require explanation 
For partially blinded studies (e.g., unblinded implanter and 
blinded assessor), document site-specific blinding plans and 
compliance 
Assess patients for success of blinding; consider assessing 
research staff 
[43,133] 
Trial stimulation Trial methods should be prespecified, standardized, and 
reported  
Account for potential biases based on type of trial stimulation   
Be clear on whether trials are performed pre- or post-
randomization and account for it in the choice of estimand and 
analysis plan 
[35] 
Minimum duration of 
treatment  
12 weeks to draw conclusions about efficacy for long-term use; 
12-24 months is preferable 
At least one year to draw conclusions about long-term safety 
Shorter studies might be appropriate for initial comparison of 





Burden of participation Assist patients in overcoming the burden of participation by 
providing adequate compensation; transportation, food, and 
lodging; rescue medication; and communication with family 
and external caregivers and by minimizing unnecessary 
procedures 
[7] 
Site Selection   
Number of sites Keep to a minimum 
Invest in recruitment methods to maximize the number of 
patients per site 
[105] 
Investigator experience Document investigator expertise with the investigational 
procedure, comparator procedures, managing patients with 
chronic pain, and performing any special outcome 
measurement procedures; specify standards for investigator 
and site selection 
[46,64] 
Comparators   
Placebo/sham Use placebo/sham comparator whenever possible; otherwise a 
finding of similar effectiveness of two active treatments cannot 
be readily interpreted 
[43,47] 
Study Population   
Diagnosis Use clear diagnostic criteria; train investigators on diagnostic 
assessment; consider central verification 
[97] 
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scale) documented over a sufficient period of time to ensure 
stability (minimum one week) 
Implement procedures to address baseline score inflation 
Failure of previous 
treatments 
Failure of previous treatments prior to SCS should be consistent 
with clinical practice guidelines and the study objectives and 
documented 
[18] 
Exclude substance abuse Use validated screening questionnaires and urine drug screen [32] 
Neuropathic pain 
component 





Exclude patients with significant levels of psychological 
comorbidities using validated tools (e.g., PHQ-9, GAD-7, Beck 
Depression Inventory, Hospital Anxiety and Depression Scale) 
[31,32,157] 
Minimum pain duration One year of moderate to severe pain [31,32] 
Patient Management   
Concomitant 
treatments 
Keep concomitant treatments constant or, if flexibility is 




Specify handling of all procedures and interactions, how they 
will be balanced by treatment arm, measured, and reported 
[15] 
Programming   
Programming Programming prescription (usage, programming parameters), 
adherence to programming prescription (usage, programming 
parameters, in alignment with subject reported outcomes), 
programming session (frequency, duration), and programming 
personnel and oversight  
Programming training and policy on qualifications of study 
personnel performing programming 
Industry should provide “best practice” algorithms as available 
Industry personnel should not generally provide programming; 
justify exceptions and how oversight is provided 
Report number of programming sessions, mean (range) time, 
personnel involved, and SCS parameters (e.g., amplitude, pulse 
width, frequency [mean/ranges], outcome of each session).  
Device usage and programming parameters used by patients 
that directly link to data collection interval. 
Compliance/adherence & persistence measure are required to 
evaluate SCS therapy.   
[6,15,49] 
Bias Control   
Expectation bias Patients should receive written, verbal, and on-line information 
that supports equipoise; all information should be made 
available 




Training   
AE reporting Train investigators and coordinators on a standardized method 
for capturing AEs; monitor consistency and completeness of AE 
reporting using risk-based monitoring techniques 
[31,48] 
Expectation Document efforts to achieve neutral expectation on the part of 
researchers and subjects 
Measure expectation at baseline and endpoint 
[3] (and Erpelding 
N, unpublished, 
2020) 
Procedures Document training and competency on test and comparator 
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Accurate pain reporting Train staff and subjects on accurate symptom reporting 
including pain intensity and location 
[32,140,151] 
Subject responsibilities Train subjects on their key responsibilities, including use of the 
SCS device, medication adherence, physical and psychological 
modalities, prohibited treatments, adverse event reporting, 




Quality control   
Risk-based monitoring Comprehensive risk-based quality management [48]( and Katz N, 
unpublished, 
2020) 
Administrative   
Funding/conflicts Disclose funding source and conflicts of interest [45,71] 
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Table 3A.  Recommendations for randomized controlled trials of spinal cord stimulation for chronic 
pain: Outcome measures and reporting 
Outcome Evaluation   
Endpoint model Describe the endpoint model in the protocol; have clear and 
aligned objectives, assessments, and endpoints 
[162] 
Primary endpoint  
 
Must be prespecified 
Adjust for multiplicity 
Specify missing data imputation method  
[25,56,156] 
Secondary endpoints Key secondary endpoints will more likely show differentiation 
between treatments if they also meet minimum baseline 
severity criteria 
 
Adverse events Prespecify the method for ascertaining AEs (e.g., open-ended, 
spontaneous, checklists, scripts) 
[80,141] 






• 0-10 numerical rating scaleb 
[27,31] 
 Physical Function 
• Brief Pain Inventory Interference Items 
• Oswestry Disability Inventory 
• Roland-Morris Disability Questionnaire 
• WOMAC Function subscale 
[28,157] 
 Emotional Functioning 
• Beck Depression Inventory 
• Hospital Anxiety and Depression Scale 
• Profile of Mood States 
[28,157] 
 Global Improvement or Satisfaction 
• Patient Global Impression of Change 
• Patient Satisfaction Scale 
• Would you do this again? 
[28] 
 Concomitant and Rescue Medications 
• Careful capture in-clinic of concomitant analgesic 
medication including dose, frequency, and reason for use 
(i.e. index or non-index pain) 
• Rescue medication use by electronic methods 
• Opioid consumption 
[6,28] 
 Patient Disposition 
• Adherence to treatment regimen: SCS and any additional 
treatments 
• Reason for early termination 
[155] 
 Sleep and Fatigue 
• MOS Sleep Scale 
• Pittsburgh Sleep Quality Index 
• Multidimensional Fatigue Inventory 
[28,157] 
 Health-Related Quality of Life 
• EQ5-D 
• SF-36 
• Quality-Adjusted Life Years (QALYs) 
[28,157] 
 Cost-effectiveness 
• Dollars per QALY 
[126] 
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• Country-specific health and social care costs 
 Work status 
• Work Productivity and Activity Impairment Questionnaire 
• Workplace Activity Limitations Scale 
• Work Limitations Questionnaire 
[157] 
 Patient preference (for crossover studies) 
• Preference scale 
[63] 
 Abuse-related events 
• MADDERS 
[153] 
 Opioid side effects 
• Opioid Side Effects Scale 
[40] 
 SCS-specific measures 
• Device survival/revision-free survival 
• Durability of analgesia 
• Adherence to SCS regimen (e.g., hours use/day) 
• Recharging burden (recharge interval, time required for 
recharge) 






Prospective monitoring for: 
• Infection (superficial, deep) 
• Cerebrospinal fluid leak 
• Hematoma 
• Stimulator pocket fluid collection 
• Wound dehiscence 
• Skin erosion 
• Allergic reaction 
• Lead migration/breakage 
• Hardware malfunction 
• Battery failure 
• Loose connection 
• Implantable pulse generator migration/discomfort 
• Dysesthesia 
• Device explantation (and reason) 





Methods • Patient characteristics and eligibility 
o Neuropathic pain assessment 
o Sensory phenotyping 
o Literacy and numeracy 
o Ability to report pain accurately 
o Level of expectation 
 
 • Blinding 
o How it is maintained and documented 
o Patient access to controllers and recharging 
 
 • Expectation 
o How balanced expectations are created and 
monitored 
o Information provided to subjects and staff 
 
 • Adherence 
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rescue medication 
o How adherence will be measured and 
documented 
 • Analysis  
o Primary estimand 
o Complete primary endpoint including primary 
analysis cohort, clinical outcome assessment, 
analysis method, handling of missing data 
o All secondary endpoints (secondary endpoints can 
be considered for claims if appropriate 
procedures for handling multiple endpoints are 
implemented) 
o Confidence intervals with interpretation 
o Handling of multiplicity for studies with multiple 
primary endpoints 
o Sample size calculation and supporting 
assumptions 
[56] 
Results Follow applicable reporting guidelines:  
 CONSORT statement [106] 
 Pain-specific supplement to CONSORT [52] 
 Recommendations for reporting crossover studies [54] 
 Recommendations for describing complex interventions [66] 
 Recommendations for reporting cost-effectiveness studies [132] 
 SCS-specific reporting recommendations:  
 Programming details  
 Position of cathode, method of placement (e.g. paresthesia 
mapping), details of trial stimulation 
 
 Description of risk-based quality management activity  
a.  Recommendations are not meant to be prescriptive; measures are provided as examples and should be 
evaluated based on the study context.  Not all domains or measures will be appropriate for all studies.  Review of 
the psychometric properties of all measures should be performed for each study. 
b.  Location should be specified, e.g., index vs. non-index pain location 
c.  Note that some complications are associated with AEs and others are not. Ascertainment of specified 
complications should be prospective whether associated with AEs or not. 
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Table 3B.  Recommendations for randomized controlled trials of spinal cord stimulation for chronic 
pain: Study design and Conduct* 
Issue Recommendation References 
Overall design   
Mechanistic studies Study mechanisms of action and biomarkers in concert with 
clinical outcomes whenever possible 
[11,93,96] 
Non-inferiority designs Non-inferiority designs, if used at all, should incorporate 
internal demonstration of assay sensitivity (e.g., a successful 
superiority test to placebo control) 
[47] 
Blinding Double-blind whenever possible; claims that blinding was not 
possible require explanation 
For partially blinded studies (e.g., unblinded implanter and 
blinded assessor), document site-specific blinding plans and 
compliance 
Assess patients for success of blinding; consider assessing 
research staff 
[43,133] 
Trial stimulation Trial methods should be prespecified, standardized, and 
reported  
Account for potential biases based on type of trial stimulation   
Be clear on whether trials are performed pre- or post-
randomization and account for it in the choice of estimand and 
analysis plan 
[35] 
Minimum duration of 
treatment  
12 weeks to draw conclusions about efficacy for long-term use; 
12-24 months is preferable 
At least one year to draw conclusions about long-term safety 
Shorter studies might be appropriate for initial comparison of 





Burden of participation Assist patients in overcoming the burden of participation by 
providing adequate compensation; transportation, food, and 
lodging; rescue medication; and communication with family 
and external caregivers and by minimizing unnecessary 
procedures 
[7] 
Site Selection   
Number of sites Keep to a minimum 
Invest in recruitment methods to maximize the number of 
patients per site 
[105] 
Investigator experience Document investigator expertise with the investigational 
procedure, comparator procedures, managing patients with 
chronic pain, and performing any special outcome 
measurement procedures; specify standards for investigator 
and site selection 
[46,64] 
Comparators   
Placebo/sham Use placebo/sham comparator whenever possible; otherwise a 
finding of similar effectiveness of two active treatments cannot 
be readily interpreted 
[43,47] 
Study Population   
Diagnosis Use clear diagnostic criteria; train investigators on diagnostic 
assessment; consider central verification 
[97] 
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scale) documented over a sufficient period of time to ensure 
stability (minimum one week) 
Implement procedures to address baseline score inflation 
Failure of previous 
treatments 
Failure of previous treatments prior to SCS should be consistent 
with clinical practice guidelines and the study objectives and 
documented 
[18] 
Exclude substance abuse Use validated screening questionnaires and urine drug screen [32] 
Neuropathic pain 
component 





Exclude patients with significant levels of psychological 
comorbidities using validated tools (e.g., PHQ-9, GAD-7, Beck 
Depression Inventory, Hospital Anxiety and Depression Scale) 
[31,32,157] 
Minimum pain duration One year of moderate to severe pain [31,32] 
Patient Management   
Concomitant 
treatments 
Keep concomitant treatments constant or, if flexibility is 




Specify handling of all procedures and interactions, how they 
will be balanced by treatment arm, measured, and reported 
[15] 
Programming   
Programming Programming prescription (usage, programming parameters), 
adherence to programming prescription (usage, programming 
parameters, in alignment with subject reported outcomes), 
programming session (frequency, duration), and programming 
personnel and oversight  
Programming training and policy on qualifications of study 
personnel performing programming 
Industry should provide “best practice” algorithms as available 
Industry personnel should not generally provide programming; 
justify exceptions and how oversight is provided 
Report number of programming sessions, mean (range) time, 
personnel involved, and SCS parameters (e.g., amplitude, pulse 
width, frequency [mean/ranges], outcome of each session).  
Device usage and programming parameters used by patients 
that directly link to data collection interval. 
Compliance/adherence & persistence measure are required to 
evaluate SCS therapy.   
[6,15,49] 
Bias Control   
Expectation bias Patients should receive written, verbal, and on-line information 
that supports equipoise; all information should be made 
available 




Training   
AE reporting Train investigators and coordinators on a standardized method 
for capturing AEs; monitor consistency and completeness of AE 
reporting using risk-based monitoring techniques 
[31,48] 
Expectation Document efforts to achieve neutral expectation on the part of 
researchers and subjects 
Measure expectation at baseline and endpoint 
[3] (and Erpelding 
N, unpublished, 
2020) 
Procedures Document training and competency on test and comparator 
procedures and ancillary care 
[46] 
Accurate pain reporting Train staff and subjects on accurate symptom reporting 
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Subject responsibilities Train subjects on their key responsibilities, including use of the 
SCS device, medication adherence, physical and psychological 
modalities, prohibited treatments, adverse event reporting, 




Quality control   
Risk-based monitoring Comprehensive risk-based quality management [48]( and Katz N, 
unpublished, 
2020) 
Administrative   
Funding/conflicts Disclose funding source and conflicts of interest [45,71] 
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Figure 1A.  Types of generators.  All SCS systems include an external, portable (battery powered) 
transmitter that emits (and in some cases receives) a wireless or radiofrequency signal providing 
telemetry and/or power. The implanted pulse generator, on the other hand, might contain a battery 
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